[Ivermectin for COVID-19]
Donato M, Garcia Martà S, Alfie V, Klappenbach R, Augustovski F, Ciapponi A, Bardach A, Alcaraz A, Pichon Riviere A
Record ID 32018002309
Spanish
Original Title:
Ivermectina para COVID-19
Authors' recommendations:
Very-low quality evidence does not allow to draw conclusions on the efficacy and safety of ivermectin use for the treatment of patients with diagnosed COVID-19. There are promising results on critical and important outcomes, such as reduced mortality, reduced inflammatory markers and viral clearance by PCR for ivermectin use in different combinations and doses, compared with standard of care in patients with mild to severe disease. However, the current methodological limitations do not allow to positively recommend ivermectin for patients with COVID-19. Also, these studies did not show differences when compared to standard of care for other important outcomes such as clinical improvement, disease progression, and incidence of viral clearance by PCR at seven days or in the incidence of serious adverse events.
Details
Project Status:
Completed
Year Published:
2021
URL for published report:
https://www.iecs.org.ar/publicacion/?id=20248
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- COVID-19
- SARS-CoV-2
- Coronavirus Infections
- Ivermectin
- Drug Therapy
- Antiparasitic Agents
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.